Document Detail


The effect on HDL cholesterol of oxprenolol and atenolol.
MedLine Citation:
PMID:  6130595     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In 19 healthy men aged 50 with untreated mild essential hypertension (WHO group I classification) randomized into two groups, treatment (18 weeks) with oxprenolol (n = 10) lowered HDL cholesterol by 11.4% (P less than 0.02) and cholesterol ratio (HDL cholesterol X 100/LDL + VLDL cholesterol) by 13.7% (P less than 0.05) whereas atenolol (n = 9) lowered HDL cholesterol by 16.5% (P less than 0.02) and cholesterol ratio by 19.2% (P less than 0.01). In the total material (n = 19) the reduction of HDL cholesterol correlated positively with initial concentration of HDL (r = 0.48, P less than 0.05). Increments of total triglycerides by 20.0 and 17.9%, respectively, for the two drugs and small changes in total cholesterol, LDL + VLDL cholesterol and uric acid were not significant. The HDL cholesterol lowering effect of oxprenolol and atenolol observed in the present study may have clinical importance since such metabolic side effects have been postulated to counteract the beneficial effect of blood pressure reduction on development of atherosclerosis and coronary heart disease in mild essential hypertension.
Authors:
S E Kjeldsen; I Eide; P Leren; O P Foss; I Holme; I L Eriksen
Related Documents :
10052025 - Influence of baseline values. i: effects on plasma total cholesterol and triglyceride l...
7942585 - Relationship between dietary intake, lipoproteins, and apolipoproteins in taipei and fr...
6615245 - Effects of anti-hypertensive therapy on serum lipoproteins. treatment with metoprolol, ...
17536125 - Pistachio nut consumption and serum lipid levels.
3198035 - Reduction of benzo[a]pyrene-induced forestomach neoplasms in mice given nitrite and die...
10052025 - Influence of baseline values. i: effects on plasma total cholesterol and triglyceride l...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Scandinavian journal of clinical and laboratory investigation     Volume:  42     ISSN:  0036-5513     ISO Abbreviation:  Scand. J. Clin. Lab. Invest.     Publication Date:  1982 Sep 
Date Detail:
Created Date:  1983-03-17     Completed Date:  1983-03-17     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0404375     Medline TA:  Scand J Clin Lab Invest     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  449-53     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / pharmacology
Atenolol / pharmacology*
Blood Pressure / drug effects
Cholesterol / blood*
Cholesterol, HDL
Cholesterol, LDL
Cholesterol, VLDL
Heart Rate / drug effects
Humans
Hypertension / drug therapy*
Lipoproteins, HDL / blood*
Lipoproteins, LDL / blood
Lipoproteins, VLDL / blood
Male
Middle Aged
Oxprenolol / pharmacology*
Propanolamines / pharmacology*
Triglycerides / blood
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Cholesterol, HDL; 0/Cholesterol, LDL; 0/Cholesterol, VLDL; 0/Lipoproteins, HDL; 0/Lipoproteins, LDL; 0/Lipoproteins, VLDL; 0/Propanolamines; 0/Triglycerides; 29122-68-7/Atenolol; 57-88-5/Cholesterol; 6452-71-7/Oxprenolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Prevention and therapy of delirium tremens with tiapride and chlordesmethyldiazepam
Next Document:  Retrograde colonic spread of sulphasalazine enemas.